Buyukkoroglu G,Şenel B,Yenilmez E .1974 .Vaginal suppositories with siRNA and paclitaxel-incorporated solid lipid nanoparticles for cervical cancer: Preparation and in vitro evaluation. Methods Mol Biol, : 303-328.
Heeren AM,van Luijk IF,Lakeman J .2019 .Neoadjuvant cisplatin and paclitaxel modulate tumorinfiltrating T cells in patients with cervical cancer. Cancer Immunol Immunother., 68(11) : 1759-1767.
Kumar L,Harish P,Malik PS .2018 .Chemotherapy and targeted therapy in the management of cervical cancer. Curr. Probl. Cancer, 42(2) : 120-128.
Li J,Chen L,Liu Q,Tang M,Wang Y,Yu J .2018 .Buformin suppresses proliferation and invasion via AMPK/S6 pathway in cervical cancer and synergizes with paclitaxel. Cancer Biol, 19(6) : 507-517.
Li J,Chen Q,Deng Z Q .2019 .KRT17 confers paclitaxel-induced resistance and migration to cervical cancer cells. Life Sci, 224 : 255-262.
Liu JJ,Ho JY,Lee HW .2019 .Inhibition of phosphatidylinositol 3-kinase (pi3k) signaling synergistically potentiates antitumor efficacy of paclitaxel and overcomes paclitaxel-mediated resistance in cervical cancer. Int. J. Mol. Sci, 20(14) : 3383.
Mao BD,Xu P,Xu P,Zhong Y,Ding WW,Meng QZ .2019 .LINC00511 knockdown prevents cervical cancer cell proliferation and reduces resistance to paclitaxel. , 44(2) : 44.
Marquina G,Manzano A,Casado A .2018 .Targeted agents in cervical cancer: beyond bevacizumab. Curr. Oncol. Rep, 20(5) : 40.
Nakamura F,Seino M,Suzuki Y .2019 .Successful management of cutaneous lymphangitis carcinomatosa arising from cervical cancer with paclitaxel-cisplatin and bevacizumab combination therapy: A case report and review of the literature. J. Med. Case Rep, 13(1) : 328.
Qiu H,Li J,Liu Q,Tang M,Wang Y .2018 .Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel. Cell Cycle, 17(10) : 1235-1244.
Rosen VM,Guerra I,McCormack M .2017 .Systematic review and network meta-analysis of bevacizumab plus first-line topotecan-paclitaxel or cisplatin-paclitaxel versus non-bevacizumabcontaining therapies in persistent, recurrent, or metastatic cervical cancer. Int. J. Gynecol Cancer, 27(6) : 1237-1246.
Seber S,Sirin DY,Yetisyigit T,Bilgen T .2020 .Piperlongumine increases the apoptotic effect of doxorubicin and paclitaxel in a cervical cancer cell line. Niger J. Clin. Pract, 23(3) : 386-391.
Tewari KS,Sill MW,Penson RT .2017 .Bevacizumab for advanced cervical cancer: Final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). , 390(10103) : 1654-1663.
Wang YT,Li B,Li XG,Ma SK,Zhang R,Wu LY .2019 .fficacy and side effect analysis of paclitaxel liposome for neoadjuvant chemotherapy in locally advanced cervical cancer. Zhonghua Fu Chan Ke Za Zhi., 54(9) : 588-594.
Wei Y,Pu X,Zhao L .2017 .Preclinical studies for the combination of paclitaxel and curcumin in cancer therapy (Review). Oncol. Rep, 37(6) : 3159-3166.
Yavas G,Yavas C,Sen E,Oner I,Celik C,Ata O C .2019 .Adjuvant carboplatin and paclitaxel after concurrent cisplatin and radiotherapy in patients with locally advanced cervical cancer. Int. J. Gynecol Cancer, 29(1) : 42-47.
Yu J,Zhao Y,Liu C Y .2020 .Synergistic anti-tumor effect of paclitaxel and miR-34a combined with ultrasound microbubbles on cervical cancer in vivo. Clin. Transl, 22(1) : 60-69.
Zagouri F,Korakiti AM,Zakopoulou R .2019 .Taxanes during pregnancy in cervical cancer: A systematic review and pooled analysis. Cancer Treat Rev., 79 : 101885.
Zhang L,Zheng CY,Cao JH,Luo SL .2020 .Efficacy of paclitaxel, carboplatin and bevacizumab for cervical cancer: A protocol for systematic review and metaanalysis. Medicine (Baltimore), 99(24) : e20558.